{# ── Billing problem banner: payment failed (past_due) or retries exhausted (unpaid). Pro access is gated off by is_pro until the card is fixed, so prompt the user to update billing. ── #}

Red Flags Detected

  • Material Weakness (worsened) — Material weaknesses now specifically identified as IT/QuickBooks controls and Purchase-to-Pay controls, providing more detail on scope than prior year's generic disclosure.
  • Goodwill Impairment (new) — Company recorded $8.4M goodwill impairment in Q1 2026 due to sustained market-cap decline.
  • Asset Impairment (new) — Company recorded $3.7M IPR&D asset impairment in Q1 2026 reflecting heightened uncertainty in advancing AKTX-101 under current capital constraints.
NASDAQ: AKTX Akari Therapeutics Plc 10-Q

AKTX posts $12M impairment on Peak Bio assets; control weaknesses persist into 2026

Filed May 19, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 14, 2025 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade AKTX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov

Generated by AI · May 26, 2026 7:37 AM